Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year
Company raises 2026 revenue guidance to $46-48 million
Strengthened balance sheet with $46 million public equity offering completed in October 2026
HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2026.
"We posted record revenue for the second consecutive quarter," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers. Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters."
Matt Lowell, Teknova's Chief Financial Officer, added, "We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $46-48 million and maintaining our expectations for full-year Free Cash Outflow of less than $8 million," he explained. "We are also pleased with the balance sheet flexibility we achieved with our $46 million equity capital raise in October and that we were able to welcome a significant number of new investors to Teknova's shareholder base through the offering," he added.
Corporate and Financial Updates
-
Third quarter 2026 total revenue of $12.7 million, up 22% compared to $10.5 million for the third quarter 2025
-
On October 22, 2026, closed an underwritten public offering of 9,200,000 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $5.00 per share, for gross proceeds of $46.0 million and net proceeds of approximately $42.9 million
-
Total cash and short-term investments were $16.6 million and total borrowings were $13.2 million at the end of the third quarter 2026
-
Expanded its modular manufacturing platform with the launch of the Fill-Tek™ Dispensing System, which provides greater flexibility for customers to order the exact single-use bag sizes, quantities, and fill volumes their process requires across RUO, RUO+, and GMP grades, with no added turnaround time
Revenue for the Third Quarter 2026
For the Three Months Ended September 30,
For the Nine Months Ended September 30,
(Dollars in thousands)
2026
2025
2026
2025
Lab Essentials
$
9,034
$
8,308
$
26,613
$
24,217
Clinical Solutions
3,168
1,706
7,741
4,928
Other
502
440
1,612
1,391
Total revenue
$
12,704
$
10,454
$
35,966
$
30,536
Third Quarter 2026 Financial Results
Total revenue for the third quarter 2026 was $12.7 million, up 22% compared to $10.5 million in the third quarter 2025. Lab Essentials revenue was $9.0 million in the third quarter 2026, up 9% compared to $8.3 million in the third quarter 2025. Clinical Solutions revenue was $3.2 million in the third quarter 2026, up 86% compared to $1.7 million in the third quarter 2025.
Gross profit for the third quarter 2026 was $4.8 million, compared to $3.2 million in the third quarter 2025. Gross margin for the third quarter 2026 was 38.0%, compared to 30.7% in the third quarter 2025. The increase in gross margin was primarily driven by higher revenue and, to a lesser extent, lower fixed cost absorption into cost of goods sold from changes in finished goods inventory levels, partially offset by higher variable costs.
Operating expenses for the third quarter 2026 were $8.0 million, compared to $7.2 million in the third quarter 2025. The increase was primarily driven by higher spending in sales and marketing, a result of higher headcount, coupled with slightly increased general and administrative expenses, partially offset by lower stock-based compensation expense.
Net loss for the third quarter 2026 was $3.5 million, or negative $0.06 per diluted share, compared to $4.3 million, or negative $0.08 per diluted share, for the third quarter 2025. Adjusted EBITDA for the third quarter 2026 was negative $1.0 million, compared to negative $1.6 million for the third quarter 2025.
Cash used in operating activities for the third quarter 2026 was $1.3 million, compared to $2.0 million of cash used in operating activities for the third quarter 2025. Free Cash Outflow was $1.4 million for the third quarter 2026, compared to $2.4 million for the third quarter 2025.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
2026 Outlook
Teknova raises its fiscal 2026 outlook for revenue and reaffirms its fiscal 2026 outlook for Free Cash Outflow. The Company now anticipates total revenue of $46 million to $48 million for the fiscal year ending December 31, 2026 ("2026"). The Company continues to anticipate Free Cash Outflow of less than $8 million for 2026.
Upcoming Investor Conference Attendance
Craig-Hallum Alpha Select Conference (New York, NY)
November 17, 2026
Stephens Annual Investment Conference (Nashville, TN)
November 18, 2026
Conference Call and Webcast
Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link . If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company's website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova's modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow).
Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova's industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova's operating results because they exclude items that are not indicative of Teknova's core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to Teknova's anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova's business prospects, including about Teknova's profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management's current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova's control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova's products (including the potential delay to or pausing of customer orders); Teknova's assessment of fundamental indicators of future demand across its target customer base; Teknova's cash flows and revenue growth rate; Teknova's supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the "Risk Factors" section of Teknova's most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including in Teknova's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC's website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
ALPHA TEKNOVA, INC.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
For the Three Months Ended
September 30,
For the Nine Months Ended
September 30,
2026
2025
2026
2025
Revenue
$
12,704
$
10,454
$
35,966
$
30,536
Cost of sales
7,878
7,248
22,471
20,339
Gross profit
4,826
3,206
13,495
10,197
Operating expenses:
Research and development
581
542
1,744
1,675
Sales and marketing
2,348
1,747
6,598
4,960
General and administrative
4,816
4,647
14,686
15,068
Amortization of intangible assets
287
287
861
861
Total operating expenses
8,032
7,223
23,889
22,564
Loss from operations
(3,206
)
(4,017
)
(10,394
)
(12,367
)
Other expenses, net
Interest expense, net
(259
)
(190
)
(730
)
(499
)
Other adjustment to loan exit fee
—
—
—
485
Other income
9
—
20
—
Total other expenses, net
(250
)
(190
)
(710
)
(14
)
Loss before income taxes
(3,456
)
(4,207
)
(11,104
)
(12,381
)
Provision for income taxes
34
79
111
120
Net loss
$
(3,490
)
$
(4,286
)
$
(11,215
)
$
(12,501
)
Net loss per share—basic and diluted
$
(0.06
)
$
(0.08
)
$
(0.21
)
$
(0.23
)
Weighted average shares used in computing net loss per share—basic and diluted
53,694,378
53,516,986
53,641,532
53,462,768
ALPHA TEKNOVA, INC.
Condensed Balance Sheets
(Unaudited)
(In thousands)
As of September 30,
As of December 31,
2026
2025
ASSETS
Current assets:
Cash and cash equivalents
$
6,631
$
5,912
Short-term investments, held-to-maturity
9,929
15,426
Accounts receivable, net
5,820
4,618
Inventories, net
7,477
7,054
Prepaid expenses and other current assets
1,942
1,501
Total current assets
31,799
34,511
Property, plant, and equipment, net
38,086
41,733
Operating right-of-use lease assets
12,641
14,112
Intangible assets, net
11,082
11,943
Other non-current assets
1,076
1,285
Total assets
$
94,684
$
103,584
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
1,813
$
1,378
Accrued liabilities
5,111
4,283
Current portion of operating lease liabilities
2,002
1,876
Total current liabilities
8,926
7,537
Deferred tax liabilities
989
879
Long-term debt, net
13,269
13,123
Long-term operating lease liabilities
11,716
13,270
Total liabilities
34,900
34,809
Stockholders' equity:
Preferred stock
—
—
Common stock
1
1
Additional paid-in capital
206,788
204,564
Accumulated deficit
(147,005
)
(135,790
)
Total stockholders' equity
59,784
68,775
Total liabilities and stockholders' equity
$
94,684
$
103,584
ALPHA TEKNOVA, INC.
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)
For the Three Months Ended September 30,
For the Nine Months Ended September 30,
2026
2025
2026
2025
Operating activities:
Net loss
$
(3,490
)
$
(4,286
)
$
(11,215
)
$
(12,501
)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense
3
22
8
71
Inventory reserve
355
732
1,180
1,657
Depreciation and amortization
1,589
1,591
4,758
4,761
Stock-based compensation
612
850
1,929
2,652
Deferred taxes
33
78
110
119
Accrued interest income on short-term investments
19
(62
)
26
(8
)
Amortization of discount on short-term investments
(92
)
(153
)
(237
)
(508
)
Amortization of debt financing costs
51
44
146
173
Other adjustment to loan exit fee
—
—
—
(485
)
Non-cash lease expense
14
31
43
92
Loss on disposal of property, plant, and equipment
68
—
92
19
Changes in operating assets and liabilities:
Accounts receivable
(415
)
(17
)
(1,210
)
(894
)
Inventories
(921
)
(36
)
(1,603
)
(1,770
)
Prepaid expenses and other current assets
(1,181
)
(1,424
)
(869
)
(1,464
)
Other non-current assets
51
33
209
67
Accounts payable
350
(136
)
508
244
Accrued liabilities
1,676
753
1,017
(399
)
Other
—
—
—
(10
)
Cash used in operating activities
(1,278
)
(1,980
)
(5,108
)
(8,184
)
Investing activities:
Purchases of short-term investments
(3,924
)
(3,973
)
(11,792
)
(13,708
)
Maturities of short-term investments
5,500
6,000
17,500
22,000
Purchases of property, plant, and equipment
(120
)
(387
)
(466
)
(800
)
Cash provided by investing activities
1,456
1,640
5,242
7,492
Financing activities:
Proceeds from long-term debt
—
—
—
1,110
Payment of exit fee costs
—
—
—
(1,110
)
Proceeds from financed insurance premiums
428
333
428
333
Repayment of financed insurance premiums
(41
)
(94
)
(138
)
(150
)
Proceeds from exercise of stock options
62
29
241
49
Proceeds from issuance of common stock under employee stock purchase plan
—
—
54
56
Payment of debt issuance costs
—
—
—
(100
)
Cash provided by financing activities
449
268
585
188
Change in cash and cash equivalents
627
(72
)
719
(504
)
Cash and cash equivalents at beginning of period
6,004
3,276
5,912
3,708
Cash and cash equivalents at end of period
$
6,631
$
3,204
$
6,631
$
3,204
ALPHA TEKNOVA, INC.
Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures
(Unaudited)
(In thousands)
For the Three Months Ended September 30,
For the Nine Months Ended September 30,
2026
2025
2026
2025
Net loss – as reported
$
(3,490
)
$
(4,286
)
$
(11,215
)
$
(12,501
)
Add back:
Interest expense, net
(259
)
(190
)
(730
)
(499
)
Provision for income taxes
34
79
111
120
Depreciation expense
1,302
1,304
3,897
3,900
Amortization of intangible assets
287
287
861
861
EBITDA
$
(1,608
)
$
(2,426
)
$
(5,616
)
$
(7,121
)
Other and non-recurring expenses:
Stock-based compensation expense
612
850
1,929
2,652
Other adjustment to loan exit fee
—
—
—
(485
)
Adjusted EBITDA
$
(996
)
$
(1,576
)
$
(3,687
)
$
(4,954
)
For the Three Months Ended September 30,
For the Nine Months Ended September 30,
2026
2025
2026
2025
Cash used in operating activities
$
(1,278
)
$
(1,980
)
$
(5,108
)
$
(8,184
)
Purchases of property, plant, and equipment
(120
)
(387
)
(466
)
(800
)
Free Cash Flow
$
(1,398
)
$
(2,367
)
$
(5,574
)
$
(8,984
)
This press release was published by a CLEAR® Verified individual.
